Ken Uchibori

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Ken Uchibori, Naohiko Inase, Mitsugu Araki et al. · Nature Communications · 2017 · 402 citations · Full text

High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer

Ryo Ariyasu, Shingo Nishikawa, Ken Uchibori et al. · Lung Cancer · 2018 · 52 citations

Oncology, High Ratio, Osimertinib Response +11

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms

Noriko Yanagitani, Ken Uchibori, Sumie Koike et al. · Cancer Science · 2020 · 46 citations · Full text

Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation

Ray Sagawa, Seiji Sakata, Bo Gong et al. · JCI Insight · 2021 · 46 citations · Full text

Immunology, Pathology, Immunologic Mechanism +21

Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995–2017

Natsuki Takano, Ryo Ariyasu, Junji Koyama et al. · Lung Cancer · 2019 · 43 citations

Single Institutional 1995–2017, Medicine, Cancer Management +6